07.10.2022 / Deals & Cases

Deal: Wenger Vieli advised NLS Pharmaceutics on a Private Placement Transaction

Wenger Vieli advised NLS Pharmaceutics on a USD 4m private placement and conversion of existing short-term notes of USD 1.53m.

NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) is a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders.

We advised NLS Pharmaceutics on all Swiss legal aspects.

The team was led by Pascal Honold (Partner, M&A /VC/PE) and included Kevin Vangehr (Associate, M&A / VC/PE), Alessa Waibel (Associate, Financial Services) and Andrea Christen (Associate, M&A / VC/PE).